The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies." This initiative seeks innovative research addressing adverse effects of cancer therapies that develop into chronic co-morbidities or delayed sequelae. The funding is aimed at supporting various types of research that uncover the mechanisms of these side effects and their clinical characterization, ultimately leading to therapeutic approaches that can minimize or prevent long-term issues. Eligible applicants include various educational institutions, non-profits, government entities, and foreign organizations, with a particular encouragement for diverse participation. A Plan for Enhancing Diverse Perspectives (PEDP) is a required component of the application, emphasizing the need for inclusivity in research. All applications must be electronically submitted by January 5, 2025, with awards contingent on available funding and merit assessed through NIH's peer-review process. The maximum funding period is five years, and there is no cap on application budgets, although they should be justifiable to project needs. This funding opportunity addresses critical gaps in understanding cancer therapy side effects and aims to improve survivor quality of life.